- Home
- ACRS vs CTGO Comparison
ACRS vs CTGO Comparison
Compare ACRS & CTGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- CTGO
- Stock Information
- Founded
- ACRS 2012
- CTGO 2009
- Country
- ACRS United States
- CTGO United States
- Employees
- ACRS N/A
- CTGO N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- CTGO Precious Metals
- Sector
- ACRS Health Care
- CTGO Basic Materials
- Exchange
- ACRS Nasdaq
- CTGO Nasdaq
- Market Cap
- ACRS 165.7M
- CTGO 151.1M
- IPO Year
- ACRS 2015
- CTGO N/A
- Fundamental
- Price
- ACRS $1.80
- CTGO $21.44
- Analyst Decision
- ACRS Strong Buy
- CTGO Strong Buy
- Analyst Count
- ACRS 9
- CTGO 1
- Target Price
- ACRS $9.25
- CTGO $37.00
- AVG Volume (30 Days)
- ACRS 1.4M
- CTGO 87.5K
- Earning Date
- ACRS 08-07-2025
- CTGO 08-13-2025
- Dividend Yield
- ACRS N/A
- CTGO N/A
- EPS Growth
- ACRS N/A
- CTGO N/A
- EPS
- ACRS N/A
- CTGO N/A
- Revenue
- ACRS $16,789,000.00
- CTGO N/A
- Revenue This Year
- ACRS N/A
- CTGO N/A
- Revenue Next Year
- ACRS $8.11
- CTGO N/A
- P/E Ratio
- ACRS N/A
- CTGO N/A
- Revenue Growth
- ACRS N/A
- CTGO N/A
- 52 Week Low
- ACRS $1.05
- CTGO $8.85
- 52 Week High
- ACRS $5.17
- CTGO $23.95
- Technical
- Relative Strength Index (RSI)
- ACRS 62.45
- CTGO 56.48
- Support Level
- ACRS $1.75
- CTGO $20.20
- Resistance Level
- ACRS $1.92
- CTGO $22.99
- Average True Range (ATR)
- ACRS 0.09
- CTGO 1.10
- MACD
- ACRS 0.01
- CTGO 0.01
- Stochastic Oscillator
- ACRS 70.00
- CTGO 57.42
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About CTGO Contango ORE Inc.
Contango Ore Inc operates in the United States. The company is engaged in the exploration of gold, silver, and copper ores in the State of Alaska. The company's focus is the exploration of a mineral lease with the Native Village of Tetlin whose governmental entity is the Tetlin Tribal Council for the exploration of minerals near Tok, Alaska. It has formed a joint venture to advance exploration of the Tetlin Property, which is prospective for gold and associated minerals. The Peak Gold JV Property is located in the Tetlin Hills and Mentasta Mountains of eastern interior Alaska. Its exploration projects are Lucky Shot, Johnson Tract, Eagle, Hona, Shamrock, and Triple Z.